Patent intelligence · US
US 2023302008
METHODS OF ADMINISTERING INTRAVENOUS MELOXICAM IN A BOLUS DOSE
METHODS OF ADMINISTERING INTRAVENOUS MELOXICAM IN A BOLUS DOSE
Patent details — US 2023302008
- Jurisdiction
- US
- Status
- granted
- Grant date
- Sep 28, 2023
- Expiration
- Sep 23, 2043
- Applicant
- ALKERMES PHARMA IRELAND LTD [IE]
- CPC classes
- A61K 9/ 00 A I, A61K 9/ 10 A I, A61K 31/ 5415 A I, A61K 47/ 28 A I
Quick answer
US 2023302008 (METHODS OF ADMINISTERING INTRAVENOUS MELOXICAM IN A BOLUS DOSE) is held by ALKERMES PHARMA IRELAND LTD [IE]. Status: granted. Granted Sep 28, 2023. Expires Sep 23, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- ALKERMES PHARMA IRELAND LTD [IE]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 9/ 00 A I, A61K 9/ 10 A I, A61K 31/ 5415 A I, A61K 47/ 28 A I, A61K 47/ 32 A I, A61K/315415
More from ALKERMES PHARMA IRELAND LTD [IE]
Related pharmaceutical patents in our USPTO index.
-
AU 2022263543
Pharmaceutical compositions comprising sorbitan esters
granted -
WO 2023156493
FORMES CRISTALLINES DE NALTREXONE
granted -
WO 2023154894
COMPOSITIONS ET PROCÉDÉS D'IMMUNOTHÉRAPIE ANTICANCÉREUSE
granted -
CY 2022006
ΠΡΟΦΑΡΜΑΚΑ ΦΟΥΜΑΡΙΚΩΝ ΑΛΑΤΩΝ ΚΑΙ Η ΧΡΗΣΗ ΤΟΥΣ ΣΤΗΝ ΑΓΩΓΗ ΠΟΙΚΙΛΩΝ ΝΟΣΩΝ
granted -
US 2022354866
IMMEDIATE RELEASE MULTILAYER TABLET
granted -
CA 3172871
COMPOSITIONS DE POLYPEPTIDES DE FUSION D'IL-2 ET LEURS PROCEDES DE FABRICATION ET D'UTILISATION
granted -
CA 3172874
COMPOSITIONS DE POLYPEPTIDES DE FUSION D'IL-2 ET LEURS PROCEDES DE FABRICATION ET D'UTILISATION
granted
Frequently asked questions
What is US patent 2023302008?
US 2023302008 (METHODS OF ADMINISTERING INTRAVENOUS MELOXICAM IN A BOLUS DOSE) is held by ALKERMES PHARMA IRELAND LTD [IE]. Status: granted. Granted Sep 28, 2023. Expires Sep 23, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 2023302008?
ALKERMES PHARMA IRELAND LTD [IE] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.
When does US 2023302008 expire?
Our index shows an expiration date of Sep 23, 2043 (17 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.